Silence Therapeutics (SLN) Stock Overview
A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SLN Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Silence Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.80 |
| 52 Week High | US$7.91 |
| 52 Week Low | US$1.97 |
| Beta | 1.33 |
| 1 Month Change | -7.50% |
| 3 Month Change | 5.07% |
| 1 Year Change | 164.84% |
| 3 Year Change | -5.38% |
| 5 Year Change | -74.92% |
| Change since IPO | -70.26% |
Recent News & Updates
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
Feb 05
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
Jan 31Silence Therapeutics: Divesiran Targets High-Burden PV
Nov 18Recent updates
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
Feb 05Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
Jan 31Silence Therapeutics: Divesiran Targets High-Burden PV
Nov 18Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
Oct 19Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
Sep 28Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 12Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 11Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
May 06
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Mar 22These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Mar 06We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Mar 04Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Jan 28Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Dec 10Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
Oct 04Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12Shareholder Returns
| SLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | 1.6% | 3.4% |
| 1Y | 164.8% | 46.8% | 29.7% |
Return vs Industry: SLN exceeded the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: SLN exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| SLN volatility | |
|---|---|
| SLN Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: SLN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 88 | Iain Ross | www.silence-therapeutics.com |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
Silence Therapeutics plc Fundamentals Summary
| SLN fundamental statistics | |
|---|---|
| Market cap | US$276.32m |
| Earnings (TTM) | -US$88.61m |
| Revenue (TTM) | US$559.00k |
Is SLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLN income statement (TTM) | |
|---|---|
| Revenue | US$559.00k |
| Cost of Revenue | US$215.00k |
| Gross Profit | US$344.00k |
| Other Expenses | US$88.96m |
| Earnings | -US$88.61m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 61.54% |
| Net Profit Margin | -15,851.88% |
| Debt/Equity Ratio | 0% |
How did SLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 12:55 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silence Therapeutics plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Keay Nakae | Chardan Capital Markets, LLC |
| Nathaniel Calloway | Edison Investment Research |